Sac-TMT combined with Osimertinib as Induction Therapy for Stage III EGFR-mutated Non-small Cell Lung Cancer: A Single-Arm, Open-Label, Phase II Clinical Study

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: e993146fa28cc4edb4f3cef8532cb49088c395d8
First added on: Sep 12, 2026